Lichen Planus Thyroid Association
This single case-control study reports an association between lichen planus and thyroid-related measures, but its design, setting, and potential confounding limit causal and clinical interpretation.
Evidence
This case-control study evaluated the association between lichen planus and thyroid disorders in an Iranian dermatology-clinic population. It included people with cutaneous lichen planus and lichen planopilaris, alongside age- and sex-matched controls. The researchers recruited patients consecutively at Razi Hospital in Tehran, and a dermatologist confirmed lichen planus through clinical evaluation and biopsy. The stated sample comprised 70 patients with lichen planus and 70 matched controls. pmid:42763630
The investigators collected medical histories, medication information, and body mass index. Their serological assessment included thyroid-stimulating hormone, free thyroxine, total triiodothyronine, and anti-thyroid peroxidase antibodies. Thyroid-stimulating hormone and total triiodothyronine were measured using electrochemiluminescence with a ROCHE kit, while anti-TPO antibodies and free thyroxine were measured by ELISA. These methods describe laboratory comparisons rather than longitudinal follow-up or an intervention. pmid:42763630
The clearest reported group difference was for anti-TPO antibodies: the lichen planus group had a mean level of 160.8 AU/mL versus 106.5 AU/mL in controls, with a mean difference of 54.3 AU/mL (95% CI: 36.1–72.5; p < 0.001). The report also states that anti-TPO antibody levels were higher in both cutaneous lichen planus and lichen planopilaris than in controls. The authors concluded that their findings supported an association between lichen planus and thyroid disorders, particularly hypothyroidism. pmid:42763630
Analysis — Interpreting an Association
The study is most useful as an observational signal of co-occurrence between lichen planus and thyroid-related laboratory findings in the population examined. Its matched-control design makes the comparator explicit, and diagnostic confirmation of lichen planus by clinical evaluation and biopsy supports the definition of the dermatologic study group. However, comparing groups at one research setting cannot establish whether thyroid abnormalities preceded lichen planus, followed it, or share causes with it. pmid:42763630
The anti-TPO result is statistically precise in this sample because its reported confidence interval excludes zero and its p-value is below the conventional threshold used in the report. Statistical significance, however, is not clinical significance. The result describes a difference in group-average antibody levels, not the diagnostic accuracy of anti-TPO testing, the prevalence of a thyroid diagnosis, or outcomes for an individual person. The reported association should therefore be read as evidence for further investigation rather than proof of a causal thyroid mechanism for lichen planus. pmid:42763630
The inclusion of both cutaneous lichen planus and lichen planopilaris adds subtype-level context, since the report describes elevated anti-TPO antibodies relative to controls in both groups. At the same time, the source does not make the observed laboratory association equivalent to a uniform clinical phenotype across those subtypes. A single-study explainer should keep the reported comparator and effect estimate central while separating them from broader conclusions about mechanisms, diagnosis, or management. pmid:42763630
Limitations
The authors state that the sample size may restrict generalizability. The research was conducted in one dermatology clinic in Tehran and enrolled an Iranian population, so the findings may not characterize other clinical settings or populations. The study controlled for age and sex through matching, but the authors also note that confounding factors affecting interpretation of thyroid disease relationships are complex and were not addressed comprehensively. pmid:42763630
The source reports some thyroid-related measures and subtype comparisons, but the presented evidence does not establish causal direction, clinical benefit from testing, or patient-specific implications. The authors call for larger studies with more rigorous designs to validate the findings and address the stated limitations. pmid:42763630
Evidence boundary
This one-source briefing is limited to what the cited study reports. It does not establish independent confirmation, broader clinical effectiveness, or patient-specific guidance. The design, population, measurements, and follow-up described in that source define the evidence boundary. This summary provides research context and is not medical advice. The evidence should be read as a bounded report of the study rather than as a conclusion about other populations, settings, interventions, or outcomes. Any possible connection to disease mechanisms remains limited to the measurements and interpretations documented by the cited authors. Terms describing associations, responses, or biological patterns retain the meaning and uncertainty given in that source.
No inference beyond the cited source is made here.